Get started

Financials · CTSO

Cytosorbents Corporation (CTSO) financials

For the twelve months ended Jun 30, 2026, Cytosorbents Corporation reported $37.22M of revenue and -$18.21M of net income.

Revenue, TTM
$37.22M
Revenue growth, YoY
+3.1%
Net income, TTM
-$18.21M
Net margin
-48.9%
Free cash flow, TTM
-$9.30M
EPS, diluted, TTM
-$0.29
Cash
$4.41M
Total debt
$17.24M
P/S
0.49
Market cap
$18.4M
Annual revenue$37.06M
FY2016FY2025
Annual net income-$8.20M
FY2016FY2025
Annual free cash flow-$12.54M
FY2016FY2025

CTSO revenue and earnings growth

CTSO revenueQ2 2026$9.63M

Quarter YoY
+0.2%
QoQ
+8.7%
FY YoY
+4.1%
5Y CAGR
-2.0%
10Y CAGR
+22.7%

CTSO revenue was $9.63M in fiscal Q2 2026 (ended Jun 30, 2026), up 0.2% from a year earlier and up 8.7% from the prior quarter. For the full fiscal 2025 it was $37.06M, up 4.1% from fiscal 2024. Compound annual growth was -2.0% over 5 years and +22.7% over 10 years. It rose in 8 of the last 10 fiscal years.

CTSO net incomeQ2 2026-$4.42M

CTSO net income was -$4.42M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $1.95M a year earlier. For the full fiscal 2025 it was -$8.20M, compared with -$20.72M in fiscal 2024.

CTSO EPSQ2 2026-$0.07

CTSO diluted EPS was -$0.07 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0.03 a year earlier. For the full fiscal 2025 it was -$0.13, compared with -$0.38 in fiscal 2024.

CTSO free cash flowQ2 2026-$597.0K

CTSO free cash flow was -$597.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.55M a year earlier. For the full fiscal 2025 it was -$12.54M, compared with -$14.71M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$37.06M$35.59M$31.08M$34.69M$43.17M$41.00M$24.95M$22.50M$15.15M$9.53M
Cost of revenue$10.57M$10.71M$9.13M$13.96M$11.05M$11.05M$7.36M$7.49M$5.52M$3.95M
Gross profit$26.49M$24.89M$21.95M$20.73M$32.12M$29.95M$17.59M$15.01M$9.63M$5.57M
Research and development--$15.73M$15.12M$16.38M$8.81M$12.09M$7.72M$3.22M$4.07M
Selling, general and admin$35.65M$33.73M$38.31M$34.29M$35.75M$28.46M$22.01M$20.87M$14.91M$11.81M
Operating income-$14.75M-$16.45M-$31.95M-$31.52M-$22.74M-$10.37M-$18.97M-$15.58M-$9.84M-$11.49M
Pre-tax income-$8.60M-$22.41M-$30.06M-$33.91M-$25.29M-$8.96M-$20.36M-$17.83M-$9.14M-$12.08M
Income tax-$401.0K-$1.69M-$813.7K-$1.09M-$736.0K-$1.13M-$1.09M-$619.5K-$676.7K-$318.6K
Net income-$8.20M-$20.72M-$29.25M-$32.81M-$24.56M-$7.84M-$19.27M-$17.21M-$8.46M-$11.76M
EPS, basic-$0.13-$0.38-$0.65-$0.75-$0.57-$0.20-$0.60-$0.56-$0.32-$0.46
EPS, diluted-$0.13-$0.38-$0.65-$0.75-$0.57-$0.20-$0.60-$0.56-$0.32-$0.46
Diluted shares62.2M54.4M44.7M43.6M43.4M38.8M32.3M30.7M27.6M25.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$6.25M$9.76M$15.62M$23.83M$53.83M$71.42M$12.23M$22.37M$17.32M$5.25M
Short-term investments---------$0
Receivables$7.55M$7.32M$6.06M$5.66M$4.52M$5.16M$4.47M$3.94M$2.21M$1.43M
Inventory$5.28M$2.73M$3.38M$3.46M$4.77M$2.67M$2.11M$833.1K$795.7K$834.0K
Current assets$20.63M$21.60M$25.40M$33.76M$64.30M$82.45M$20.90M$28.26M$20.74M$7.83M
Total assets$44.18M$47.37M$52.96M$63.23M$89.52M$89.95M$27.38M$34.20M$24.10M$9.69M
Current liabilities$9.71M$9.82M$14.04M$9.71M$13.69M$10.15M$9.94M$6.92M$7.85M$4.28M
Short-term debt--$2.50M--$0$1.67M$666.7K$4.00M$833.3K
Long-term debt$16.67M$14.00M$2.54M$5.00M-$0$13.39M$9.27M$5.99M$4.08M
Total debt$16.67M$14.00M$5.04M$5.00M-$0$15.05M$9.94M$9.99M$4.91M
Total liabilities$38.28M$36.27M$29.48M$27.86M$26.94M$10.73M$23.96M$17.26M$13.84M$8.36M
Shareholders' equity$5.90M$11.11M$23.48M$35.37M$62.58M$79.22M$3.42M$16.93M$10.26M$1.34M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$12.38M-$14.43M-$21.66M-$28.23M-$14.01M-$5.61M-$16.76M-$10.84M-$6.46M-$6.73M
Capital expenditures$164.0K$284.0K$538.1K$6.09M$3.64M$708.4K$698.2K$672.0K$990.7K$140.7K
Free cash flow-$12.54M-$14.71M-$22.19M-$34.32M-$17.65M-$6.32M-$17.46M-$11.51M-$7.45M-$6.87M
Investing cash flow-$415.0K-$669.0K-$936.2K-$6.46M-$4.28M-$1.68M-$1.52M-$1.52M-$1.68M$1.60M
Financing cash flow$9.31M$9.33M$14.47M$4.96M$715.2K$66.35M$8.18M$17.47M$20.12M$5.06M
Stock-based compensation$2.77M$3.76M$4.16M$3.42M$4.02M$3.51M$1.67M$4.44M$3.31M$2.76M
Depreciation and amortization$1.23M$1.33M$1.46M$882.6K$731.6K$660.8K$581.5K$390.6K$218.3K$161.6K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY4.1%14.5%-10.4%-19.6%5.3%64.4%10.9%48.5%59.0%98.8%
Gross margin71.5%69.9%70.6%59.8%74.4%73.0%70.5%66.7%63.6%58.5%
Operating margin-39.8%-46.2%-102.8%-90.9%-52.7%-25.3%-76.0%-69.3%-65.0%-120.6%
Net margin-22.1%-58.2%-94.1%-94.6%-56.9%-19.1%-77.2%-76.5%-55.8%-123.5%
Free cash flow margin-33.8%-41.3%-71.4%-98.9%-40.9%-15.4%-70.0%-51.2%-49.2%-72.1%
Return on equity-138.9%-186.5%-124.6%-92.8%-39.2%-9.9%-563.6%-101.6%-82.4%-879.5%
Return on assets-18.6%-43.7%-55.2%-51.9%-27.4%-8.7%-70.4%-50.3%-35.1%-121.3%
Current ratio2.132.201.813.484.708.122.104.092.641.83
Debt to equity2.821.260.210.14-0.004.400.590.973.67

Source: XBRL data Cytosorbents Corporation files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CTSO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CTSO$37.22M+3.1%-$18.21M-48.9%$18.4M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

CTSO FAQ

9 questions
  • What is CTSO revenue?
    Cytosorbents Corporation (CTSO) reported $37.22M of revenue for the twelve months ended Jun 30, 2026. That is up 3.1% from the year before. Revenue for fiscal 2025 was $37.06M.
  • Is CTSO profitable?
    No. Cytosorbents Corporation reported a net loss of $18.21M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does CTSO have?
    Cytosorbents Corporation reported $4.41M in cash and cash equivalents and $17.24M of debt on its most recent balance sheet in SEC filings.
  • How fast is CTSO revenue growing?
    Cytosorbents Corporation's revenue changed +4.1% in fiscal 2025, to $37.06M. Its compound annual growth rate was -2.0% over 5 years and +22.7% over 10 years.
  • What is CTSO gross margin?
    Cytosorbents Corporation's gross profit was $26.65M on $37.22M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 71.6%.
  • What is CTSO free cash flow?
    Cytosorbents Corporation generated -$9.30M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$9.15M less capital expenditures.
  • What is CTSO earnings per share?
    Diluted earnings per share were -$0.29 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CTSO last report financial results?
    The latest statements here come from Cytosorbents Corporation's 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.
  • Where does this CTSO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cytosorbents Corporation files with the SEC. It is provided for information only and is not investment advice.